Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Journey Medical (Nasdaq: DERM) expanded payer access for Emrosi™, increasing commercial lives reached from approximately 100 million to over 150 million as of April 1, 2026.

Rhea-AI Summary

Journey Medical (Nasdaq: DERM) expanded payer access for Emrosi™, increasing commercial lives reached from approximately 100 million to over 150 million as of April 1, 2026.

Approximately 85% of U.S. commercial lives now have access after contracting with a third major GPO. The company expects expanded access to support prescription growth and improved brand profitability as formulary adoption progresses through 2026.

Positive

• Payer reach expanded from ~100M to >150M commercial lives
• 85% of U.S. commercial lives now have access to Emrosi
• Contracts secured with three major GPOs for Emrosi

Negative

• Formulary adoption and conversion of access into coverage remain in progress through 2026

Argus Apr 21 session

-3.88% close to close Open Argus

Details

News Market Reaction – FBIO

On Apr 21, the day this news came out, FBIO closed 3.88% below the previous close.

Data tracked by StockTitan Argus for the Apr 21 session.

Market Context

This announcement highlights a key commercial milestone for Emrosi™, expanding payer access from app...

Analysis

This announcement highlights a key commercial milestone for Emrosi™, expanding payer access from approximately 100 million to over 150 million commercial lives and reaching about 85% of U.S. commercial lives. It builds on Journey’s earlier disclosure that Emrosi™ generated $14.7 million in 2025 net revenue. Investors may watch how increased health plan formulary adoption translates into prescription growth, reductions in reliance on co-pay support programs, and any resulting improvements in overall profitability for Journey and its parent Fortress.

Key Figures

Initial payer access: approximately 100 million commercial lives Expanded payer access: over 150 million commercial lives Coverage breadth: approximately 85% of all U.S. commercial lives +3 more

Initial payer access

approximately 100 million commercial lives

Emrosi™ commercial access prior to April 1, 2026

Expanded payer access

over 150 million commercial lives

Emrosi™ commercial access as of April 1, 2026

Coverage breadth

approximately 85% of all U.S. commercial lives

Payer access to Emrosi™ after third GPO contract

Emrosi total dose

40 mg

Minocycline Hydrochloride Modified-Release Capsules strength

Immediate-release dose

10 mg

Immediate-release component of Emrosi™ capsules

Extended-release dose

30 mg

Extended-release component of Emrosi™ capsules

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Full-year results

   24h Move

   -11.5%

   Reported 2025 results with ZYCUBO approval and major asset monetizations.

2. Mar 30

   Asset sale

   24h Move

   +3.3%

   Closed $205M PRV sale, with Fortress expecting over $100M in proceeds.

3. Mar 25

   Journey earnings

   24h Move

   -3.7%

   Journey reported 2025 revenue growth and Emrosi™ launch contribution.

4. Mar 18

   Earnings date set

   24h Move

   +1.3%

   Announced timing and webcast details for Journey’s 2025 results release.

5. Feb 23

   PRV sale deal

   24h Move

   +2.7%

   Cyprium agreed to sell a PRV for $205M, with royalties and milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

group purchasing organization, gpo, modified-release, extended release, +3 more

7 terms

group purchasing organization financial

"after contracting with the third major group purchasing organization (GPO)."

A group purchasing organization (GPO) is an entity that helps a group of buyers, such as healthcare providers or businesses, combine their purchasing power to buy goods or services at lower prices. By negotiating on behalf of its members, a GPO can secure better deals than individual buyers could on their own. This can lead to cost savings and operational efficiencies, making GPOs important players in industries where large-scale purchasing influences overall expenses and profitability.

gpo financial

"after contracting with the third major group purchasing organization (GPO)."

A GPO, or group purchasing organization, is an entity that negotiates bulk-buying discounts on supplies, equipment, or services on behalf of multiple member organizations, commonly hospitals, clinics, or retailers. For investors, a GPO matters because it can lower costs for members, increase predictable revenue through membership fees or contracts, and influence supplier pricing power—similar to how a shoppers’ club secures lower prices by pooling many buyers into one large order.

modified-release medical

"Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate"

Modified-release describes a drug formulation designed to release its active ingredient slowly, at specific times, or in particular parts of the body instead of all at once. For investors, this matters because such formulations can improve patient convenience and treatment results, extend commercial life or market exclusivity, and create differentiation from competitors—think of it like a timed sprinkler that delivers water steadily rather than a single sudden shower.

extended release medical

"Modified-Release Capsules, 10 mg immediate release and 30 mg extended release)"

An extended release medicine is formulated to release its active ingredient slowly over a longer period than an immediate-release version, so patients take fewer doses while keeping drug levels steadier in the body. For investors, this matters because extended-release products can improve patient adherence, differentiate a drug from competitors, support higher pricing or longer commercial life, and face distinct regulatory and patent considerations that affect sales and risk.

rosacea medical

"Emrosi™ is for the treatment of inflammatory lesions of rosacea in adults."

Rosacea is a chronic skin condition that causes persistent facial redness, visible blood vessels, occasional pimple-like bumps and sometimes eye irritation; think of it as a blush that won’t fully fade and can flare with triggers like heat or stress. It matters to investors because its long-term nature and high prevalence create steady demand for prescription treatments, over-the-counter products and cosmetic procedures, influencing revenue and R&D priorities in dermatology and pharmaceutical markets.

formulary regulatory

"Our efforts remain on health plan formulary adoption, on both a national and regional"

A formulary is a list of prescription drugs that a health insurer, hospital system, or government program has approved for coverage and payment. Think of it like an approved menu or shopping list that determines which medicines patients can get with financial help. For investors, formulary placement affects a drug maker’s potential sales, pricing power and market access, so being included—or excluded—can materially change a company’s revenue outlook.

co-pay bridging program financial

"we expect there to be less reliance on our co-pay bridging program and an improvement"

A co-pay bridging program temporarily covers or reduces a patient’s out-of-pocket cost for a prescription until insurance, assistance programs, or long-term coverage takes effect. Think of it like a short-term loan or coupon that removes the immediate price barrier so more patients can start a treatment; for investors this can speed sales uptake, improve revenue predictability, and carry costs or regulatory scrutiny that affect a drug maker’s margins and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026

SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately 85% of all commercial lives in the United States now have access to Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after contracting with the third major group purchasing organization (GPO). Emrosi™ is for the treatment of inflammatory lesions of rosacea in adults. Journey Medical continues to execute on the launch of Emrosi™, with expanded payer access anticipated to facilitate further growth in total prescription demand.   

“We are extremely pleased with the completion of this milestone for Emrosi™,” said Claude Maraoui, Co-Founder, President, and CEO of Journey Medical Corporation. “Our focus on delivering cost-effective access to high-quality dermatology therapies is expected to expand coverage and improve patient access, positioning Emrosi™ for sustained commercial growth. Now that our contracts have been secured with the three major GPOs, we look forward to continuing to increase coverage for Emrosi™ for patients nationwide by converting access into coverage. Our efforts remain on health plan formulary adoption, on both a national and regional level, throughout 2026 and beyond, supporting Emrosi’s™ potential to become the standard of care in rosacea and driving long-term value creation. As formulary adoption continues to increase, we expect there to be less reliance on our co-pay bridging program and an improvement in profitability for the brand.”

About Rosacea
Rosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to The National Rosacea Society, it is estimated that rosacea affects over 17 million Americans and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report that more than 90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition.

Important Safety Information
Indication: EMROSI™ is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common adverse reaction reported by ≥1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia. Contraindications: EMROSI should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines. Warnings/Precautions: Cases of anaphylaxis, serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized, discontinue EMROSI immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated Colitis occurs. Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should be cautioned about driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia, and vision loss. Discontinue EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise. Discontinue EMROSI immediately if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while using EMROSI. Tetracycline-class antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant bacteria to develop during the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute appropriate therapy. Perform periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For full prescribing information, please visit www.emrosi.com.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and future product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition because their period of exclusivity has ended or they are without patent protection, subjecting them to the potential introduction of new competitor products and/or an increase in market share of existing competitor products, either of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance on third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of Emrosi^TM and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many commercial lives does Journey Medical (DERM) now reach with Emrosi as of April 1, 2026?

Emrosi now reaches over 150 million commercial lives, up from about 100 million previously. According to the company, this expansion reflects new contracts including a third major GPO and increased national payer access.

What percentage of U.S. commercial lives have access to Emrosi (DERM) after the new GPO contract?

Approximately 85% of U.S. commercial lives now have access to Emrosi. According to the company, that access follows contracting with three major GPOs and is intended to support prescription demand growth.

What does the third major GPO contract mean for Emrosi’s commercial launch (DERM)?

The contract adds broader payer access and distribution touchpoints, supporting commercial scale. According to the company, the third major GPO helps convert access into formulary coverage and drive sustained prescription demand.

Will Journey Medical (DERM) reduce its co-pay bridging program for Emrosi as coverage grows?

The company expects reduced reliance on its co-pay bridging program as formulary adoption increases. According to the company, broader access and coverage gains are expected to improve profitability for the Emrosi brand over time.

What are Journey Medical’s (DERM) next steps for Emrosi after expanding payer access?

Journey Medical plans to pursue formulary adoption at national and regional levels throughout 2026 and beyond. According to the company, efforts focus on converting payer access into formulary coverage to support long-term commercial growth.